From the publishers of JADPRO

Cardio-Oncology Updates

.

HER2-TARGETED THERAPIES

Home HER2-Targeted Therapies News & Literature Highlights

HER2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management

This comprehensive review analyses clinical trials of trastuzumab, lapatinib, pertuzumab, T-DM1, and neratinib in breast cancer. The authors discuss incidence and mechanisms for cardiotoxicity of HER2-targeted therapies, in addition to summarizing practices in management of cardiotoxicity for routine patient care.

Breast Cancer Research and Treatment

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

View More

Videos

HER2-Targeted Therapies Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity

HER2-Targeted Therapies HER2-Targeted Therapies: Cardiotoxicity Incidence

HER2-Targeted Therapies HER2-Targeted Therapies and Cardiotoxicity: The Pharmacist Perspective

General Cardio-Oncology Welcome Message from the Program Chair

View More